magnesium sulfate heptahydrate: clinical use

Prescribing considerations

• Confirm indication, route and exact product: concentrated parenteral solution, infusion solution and Epsom Salts crystals are not interchangeable.
• Assess renal function and concurrent medicines before parenteral treatment; reduced renal clearance increases accumulation and toxicity risk.
• Administer parenteral treatment where respiratory and cardiovascular support are available; injectable calcium gluconate should be immediately accessible.
• For oral Epsom Salts, investigate severe abdominal pain or persistent constipation rather than extending laxative use.

Contraindications and cautions

• Product-specific hypersensitivity to magnesium sulfate or excipients.
• Selected parenteral products: renal failure; the concentrated product additionally lists severe renal impairment or anuria.
• Selected parenteral products: hepatic failure or hepatic encephalopathy.
• Heart block is a contraindication or reason to avoid parenteral magnesium depending on the product; myocardial damage and myasthenia gravis are contraindications for the selected concentrated product.
• Internal Epsom Salts use: acute gastrointestinal conditions other than constipation, renal impairment, intestinal parasitic disease in children, and age under 12.

Monitoring

• Serum magnesium and calcium, renal function and urine output.
• Respiratory rate, oxygenation, consciousness and tendon reflexes.
• Blood pressure, heart rate and ECG when clinically indicated.
• Injection or infusion site, particularly with concentrated solutions.
• Fetal assessment during obstetric use; consider neonatal calcium, magnesium and skeletal assessment after prolonged or repeated exposure.

Clinical pharmacology

Magnesium is predominantly intracellular, supports numerous enzyme systems and modulates neuronal and neuromuscular transmission partly through physiological calcium antagonism and NMDA-channel effects. Parenteral magnesium is cleared mainly by the kidneys, making renal impairment a major determinant of accumulation and toxicity.

Formulation and product differences

• The selected concentrated solution supports intravenous or intramuscular use and requires dilution before intravenous administration.
• The selected lower-concentration product is a clear intravenous infusion solution.
• Epsom Salts BP consists of magnesium sulfate heptahydrate crystals or crystalline powder for oral dilution or external preparation; it contains no listed excipients.

Solution for infusion

Route: Intravenous

Strengths: 10% w/v, 20% w/v

Injection

Route: Parenteral

Strengths: 1 g/10 mL, 10% w/v, 20% w/v, 50% w/v